Prof Angela M. Minassian

Employment

• University of Oxford

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (81)

• Malaria: Past, present and future
  Clinical Medicine 2024 DOI: 10.1016/j.clinme.2024.100258
  +Save
• Evaluation of Precision of thePlasmodium knowlesiGrowth Inhibition Assay forPlasmodium vivaxDuffy-Binding Protein-based Malaria Vaccine Development
  2024 DOI: 10.1101/2024.01.23.576905
  +Save
• A systematic analysis of the human immune response to Plasmodium vivax.
  The Journal of clinical investigation 2023 DOI: 10.1172/jci152463
  +Save
• Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype
  2023 DOI: 10.1101/2023.10.04.560576
  +Save
• Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5
  2023 DOI: 10.1101/2023.10.04.560669
  +Save
• PvDBPII-Matrix M elicits polyfunctional antibodies that limit parasite growth in a challenge trial
  2023 DOI: 10.1101/2023.08.01.23293515
  +Save
• Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.
  Med (New York, N.Y.) 2023 DOI: 10.1016/j.medj.2023.07.003
  +Save
• Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.
  Science translational medicine 2023 DOI: 10.1126/scitranslmed.adf1782
  +Save
• Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
  Eimear Kelly, Melanie Greenland, Philip de Whalley

  +30 more

  • Parvinder K. Aley
  • Emma L. Plested
  • Nisha Singh
  • Stanislava Koleva
  • Sharon Tonner
  • +25 more
  The Journal of infection 2023 DOI: 10.1016/j.jinf.2023.06.007
  +Save
• Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies.
  Malaria journal 2023 DOI: 10.1186/s12936-023-04591-6
  +Save
• Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
  Xinxue Liu, Alasdair Peter Stuart Munro, Shuo Feng

  +55 more

  • Leila Janani
  • Parvinder K. Aley
  • Gavin Babbage
  • David Neil Baxter
  • Marcin Bula
  • +50 more
  The Journal of infection 2023 DOI: 10.1016/j.jinf.2023.03.025
  +Save
• Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
  Xinxue Liu, Alasdair Peter Stuart Munro, Annie Wright

  +58 more

  • Shuo Feng
  • Leila Janani
  • Parvinder K. Aley
  • Gavin Babbage
  • Jonathan Baker
  • +53 more
  The Journal of infection 2023 DOI: 10.1016/j.jinf.2023.04.012
  +Save
• Superior antibody immunogenicity of a RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
  2023 DOI: 10.1101/2023.04.17.23288686
  +Save
• Analyses of vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens
  2023 DOI: 10.1101/2023.03.17.23287040
  +Save
• Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 DOI: 10.1093/cid/ciac803
  +Save
• Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine.
  JCI insight 2023 DOI: 10.1172/jci.insight.163859
  +Save
• The challenges of Plasmodium vivax human malaria infection models for vaccine development.
  Frontiers in immunology 2023 DOI: 10.3389/fimmu.2022.1006954
  +Save
• Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
  Alexander J. Mentzer, Daniel O’Connor, Sagida Bibi +67 more
  Nature medicine 2022 DOI: 10.1038/s41591-022-02078-6
  +Save
• Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics.
  Frontiers in immunology 2022 DOI: 10.3389/fimmu.2022.984323
  +Save
• Repeat controlled human malaria infection of healthy UK adults with blood-stagePlasmodium falciparum: safety and parasite growth dynamics
  2022 DOI: 10.1101/2022.06.27.22276860
  +Save